This study aimed to investigate whether serum HMGB1 levels prior to the first administration of an anti-PD-1/PD-L1 antibody may serve as a predictive blood marker for the efficacy of anti-PD-1/PD-L1 antibody monotherapy in patients with NSCLC. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.